Navigation Links
Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
Date:10/14/2008

ng months."

About REG1 Anticoagulation System

The REG1 system consists of the first specific, direct-acting anticoagulant controllable by a matched reversal agent. Regado is developing REG1 for use in patients suffering from acute coronary syndrome who undergo coronary revascularization procedures. These procedures, which include percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG), put patients at a high risk for therapy-related bleeding complications. REG1 is being developed initially to increase safety and therapeutic flexibility as well as to improve patient outcomes in coronary revascularization procedures.

REG1 is a two-component system, consisting of an aptamer-based anticoagulant and its matched reversal agent. The anticoagulant component, RB006, is a single-stranded, nucleic acid aptamer. RB006 selectively and potently binds to and inhibits factor IXa, a protein that is critical to blood coagulation. The reversal agent, RB007, is a complementary nucleic acid that specifically binds to and neutralizes RB006. The amount of RB007 administered allows physicians to rapidly fine tune the pharmacodynamic effect of RB006, from slight reduction in anticoagulation all the way to complete reversal.

About Regado Biosciences

Regado Biosciences is pioneering a new therapeutic field with the discovery and development of two-component drug systems, comprising an aptamer therapeutic that can be controlled directly by a specific and matched reversal agent. Regado's technology is designed to give physicians the ability to directly control and fine tune each product's therapeutic effect. This control and flexibility allows physicians to meet the individual needs of each patient independent of the setting. Regado initially is focusing its discovery and development efforts on acute care injectable antithrombotics, a multi-billion dollar market in need of therapeutics with improved safety profiles.

Current i
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
2. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
3. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
4. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
5. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
6. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
7. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
8. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
9. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
10. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
11. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014  Indianapolis interventional medical ... Toronto -based 3D visualization leader ... of Neurological Surgeons Annual Meeting that they have ... brain surgery. The collaboration is the first of ... to improve patient outcomes. NICO,s BrainPath® interventional access ...
(Date:10/20/2014)... SAN DIEGO , Oct. 20, 2014 /PRNewswire/ ... development of therapeutic antibodies, today announced the appointment ... Development Officer. Dr. Londei will lead the preclinical ... "We are pleased to welcome ... Hamza Suria , President and Chief Executive ...
(Date:10/20/2014)... LONDON , October 20, 2014 ... study of its novel, low volume bowel preparation, NER1006, ... of the American College of Gastroenterology (ACG), ... end point of stool weight and co-primary endpoint of ... efficacy with NER1006 vs. MOVIPREP ® in screening ...
Breaking Medicine Technology:Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2
... - Two Large-Scale Analyses Have Conflicting Results -, ... decline,in memory and thinking processes among placebo groups ... to show the effectiveness,of new Alzheimer therapies, according ... Association International Conference on Alzheimer,s,Disease (ICAD 2008) in ...
... 25 Genaera,Corporation (Nasdaq: GENR ) ... (PK) data and new preclinical data on ... treatment of type 2,diabetes and obesity, during ... in Arlington, Virginia. Dr. Michael McLane, Vice ...
Cached Medicine Technology:Controversy About Lack of Placebo Group Decline in Alzheimer's Clinical Trials 2Controversy About Lack of Placebo Group Decline in Alzheimer's Clinical Trials 3Controversy About Lack of Placebo Group Decline in Alzheimer's Clinical Trials 4Controversy About Lack of Placebo Group Decline in Alzheimer's Clinical Trials 5Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit 2Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit 3Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit 4Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit 5
(Date:10/20/2014)... Ga. (PRWEB) October 20, 2014 ... and relationship-marketing firm, announced today that William H. ... named the 2014 ISE® Luminary Leadership Award winner. ... the achievements of an outstanding leader and industry ... and contributions in advancing the information security industry. ...
(Date:10/20/2014)... Zereana Jess-Huff, a 34-year-old mother, corporate executive and ovarian cancer ... think outside the bra. She doesn’t try to hide her ... about women’s other lady parts. , "We have won the ... pink and everybody knows what you’re talking about,” Jess-Huff points ... not been won when it comes to gynecologic cancers. It ...
(Date:10/20/2014)... My Clients Plus ( http://www.MyClientsPlus.com ) today ... new module enables easy administration and routing of follow-up ... , This application allows users such as Therapists to ... to-do item to a specific client, categorize tasks the ... reminders for follow-ups. It's designed to enable easy ...
(Date:10/20/2014)... AttorneyOne.com, a recognized authority on law, update the website ... Sit and Slim II . , The FDA ... Sit and Slim II because it contains Sibutramine ... loss product on various websites and possibly in some retail ... safety reasons, can significantly increase blood pressure and/or pulse rate ...
(Date:10/20/2014)... 20, 2014 Rockynol Retirement Community ... on Oct. 14. The $11 million project will include ... a cooked-to-order kitchen with full-service restaurant style dining. , ... for first class Assisted Living apartments,” said Kara Hanzie, ... the highest quality of care and this investment is ...
Breaking Medicine News(10 mins):Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:My Clients Plus Announces New Workflow Management Software 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2
... discovered the genetic factors that make some mosquitoes resistant ... the mosquitos immune system is the key to their finding. ... parasite that causes malaria, a biochemical reaction is triggered that ... on to the parasites surface and targeting it for termination, ...
... a teenager Scot of severe asthma. ,Fifteen-year-old ... had to give up sports and physical education lessons at ... had read somewhere about the benefits of playing wind instruments ... one. ,Being a proud Glasgow-born Scot, David ...
... received the world's first face transplant 18 months ago said Friday ... in the mirror with a combination of sadness and wonder. ... have a face, a smile, facial expressions which allow them to ... an interview published in Saturday's edition of Le Monde. ...
... the allegedly substandard Chinese products make constant headlines in the ... crackdown. ,For starters it has suspended the sale ... arthritis. ,In the past week alone, a former ... sentenced to death on bribery charges, and it was announced ...
... in OK! magazine's list of 'most influential' celebrities. ... the 'beauty queen' category for her 'refreshing girl-next-door look' ... Beyonce and Jennifer Lopez behind. ,According to ... celebrities in six categories including beauty queens, style setters, ...
... has openly confessed that she had sex with former boyfriend Justin ... she was married. ,"I've only slept with one person ... relationship with Justin, and I thought he was the one. But ... The most painful thing I have ever experienced was that ...
Cached Medicine News:Health News:Genetic Factors Behind Mosquitoes Resistance to Malaria Identified 2Health News:World's First Face Transplant Patient Feels She is Alive Again 2Health News:China Cracks the Whip Against Drug Manufacturers Who Fail Quality Norms 2
... The CineScan A/B represent a true ... analog image with technology and diagnostic capability ... in the vitreous. Adjust the gain up ... would be invisible at a standard 90db ...
EchoScan US-2500 is available in a single configuration or in combination with the A scan for maximum cost efficiency....
... in the 21st century requires ... Alcon® UltraScan® imaging system responds ... at clinical echographic needs in ... permits step-by-step processing to collect ...
PremierEdge™ MVR Knives. Angled....
Medicine Products: